Metal-organic framework nanovaccines for systemic tumour regression.

MOF-Vac, a nanoscale metal-organic framework vaccine, induced tumour regression in murine models across melanoma, colorectal cancer, triple-negative breast cancer, lung cancer, and oropharyngeal cancer.

• Why it matters: Cancer vaccines often fail clinically because they cannot sustain T-cell activation within tumours, limiting durable antitumour immunity.
• What they did: The MOF-Vac platform co-delivers peptide antigens and STING agonists using high loading capacity and phosphate-triggered intracellular release, then evaluates responses in multiple mouse tumour models.
• The result: MOF-Vac produced sustained T-cell priming, intratumoural effector function, immune memory, and metastasis protection, and it synergized with radiotherapy and immune checkpoint blockade.

AI summary of the abstract · may contain errors · not medical advice · read the paper.